Personalized Prediction of Short- and Long-Term PTH Changes in Maintenance Hemodialysis Patients

被引:4
作者
Pirklbauer, Markus [1 ]
Bushinsky, David A. [2 ]
Kotanko, Peter [3 ,4 ]
Schappacher-Tilp, Gudrun [5 ,6 ]
机构
[1] Med Univ Innsbruck, Dept Internal Med Nephrol & Hypertens 4, Innsbruck, Austria
[2] Univ Rochester, Sch Med, Dept Med, Rochester, NY USA
[3] Renal Res Inst New York, New York, NY USA
[4] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
[5] Karl Franzens Univ Graz, Inst Math & Sci Comp, Graz, Austria
[6] FH Joanneum Univ Appl Sci, Inst Elect Engn, Graz, Austria
关键词
precision medicine; secondary hyperparathyroidism; parathyroid hormone; patient-level prediction model; hemodialysis; CHRONIC KIDNEY-DISEASE; PARATHYROID-HORMONE; SECONDARY HYPERPARATHYROIDISM; CINACALCET; CALCIUM; HYPERPLASIA; PHOSPHORUS;
D O I
10.3389/fmed.2021.704970
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Personalized management of secondary hyperparathyroidism is a critical part of hemodialysis patient care. We used a mathematical model of parathyroid gland (PTG) biology to predict (1) short-term peridialytic intact PTH (iPTH) changes in response to diffusive calcium (Ca) fluxes and (2) to predict long-term iPTH levels.</p> Methods: We dialyzed 26 maintenance hemodialysis patients on a single occasion with a dialysate Ca concentration of 1.75 mmol/l to attain a positive dialysate-to-blood ionized Ca (iCa) gradient and thus diffusive Ca loading. Intradialytic iCa kinetics, peridialytic iPTH change, and dialysate-sided iCa mass balance (iCaMB) were assessed. Patient-specific PTG model parameters were estimated using clinical, medication, and laboratory data. We then used the personalized PTG model to predict peridialytic and long-term (6-months) iPTH levels.</p> Results: At dialysis start, the median dialysate-to-blood iCa gradient was 0.3 mmol/l (IQR 0.11). The intradialytic iCa gain was 488 mg (IQR 268). Median iPTH decrease was 75% (IQR 15) from pre-dialysis 277 to post-dialysis 51 pg/ml. Neither iCa gradient nor iCaMB were significantly associated with peridialytic iPTH changes. The personalized PTG model accurately predicted both short-term, treatment-level peridialytic iPTH changes (r = 0.984, p < 0.001, n = 26) and patient-level 6-months iPTH levels (r = 0.848, p < 0.001, n = 13).</p> Conclusions: This is the first report showing that both short-term and long-term iPTH dynamics can be predicted using a personalized mathematical model of PTG biology. Prospective studies are warranted to explore further model applications, such as patient-level prediction of iPTH response to PTH-lowering treatment.</p>
引用
收藏
页数:7
相关论文
共 50 条
  • [21] Short and long term outcome of the surgery for the gastric cancer in patients on maintenance hemodialysis
    Hiramatsu, Kiyoshi
    Arai, Toshiyuki
    Saeki, Satomi
    Amemiya, Takeshi
    Goto, Hidenari
    Seki, Takashi
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2014, 29 : 273 - 273
  • [22] Short- and long-term uses of calcium acetate do not change hair and serum zinc concentrations in hemodialysis patients
    Hwang, SJ
    Chang, JM
    Lee, SC
    Tsai, JH
    Lai, YH
    SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION, 1999, 59 (02) : 83 - 87
  • [23] Long-Term Treatment of Hyperphosphatemia With Bixalomer in Japanese Hemodialysis Patients
    Akizawa, Tadao
    Kameoka, Chisato
    Kaneko, Yuichiro
    Kawasaki, Shigenori
    THERAPEUTIC APHERESIS AND DIALYSIS, 2013, 17 (06) : 612 - 619
  • [24] Long-term therapy with paricalcitol for secondary hyperparathyroidism in hemodialysis patients
    Pai, AB
    Lin, S
    Arruda, JAL
    Lau, AH
    INTERNATIONAL JOURNAL OF ARTIFICIAL ORGANS, 2003, 26 (06) : 484 - 490
  • [25] Impact of Long-Term Cinacalcet, Ibandronate or Teriparatide Therapy on Bone Mineral Density of Hemodialysis Patients: A Pilot Study
    Mitsopoulos, Efstathios
    Ginikopoulou, Eudoxia
    Economidou, Dominiki
    Zanos, Stavros
    Pateinakis, Panagiotis
    Minasidis, Elias
    Memmos, Dimitrios
    Thodis, Elias
    Vargemezis, Vassilis
    Tsakiris, Dimitrios
    AMERICAN JOURNAL OF NEPHROLOGY, 2012, 36 (03) : 238 - 244
  • [26] Sclerostin Quo Vadis? - Is This a Useful Long-Term Mortality Parameter in Prevalent Hemodialysis Patients?
    Nowak, Albina
    Artunc, Ferruh
    Serra, Andreas L.
    Pollock, Emily
    Krayenbuehl, Pierre-Alexandre
    Mueller, Christian
    Friedrich, Bjoen
    KIDNEY & BLOOD PRESSURE RESEARCH, 2015, 40 (03) : 266 - 276
  • [27] A long-term comparative study of calcitriol versus alphacalcidol in patients with secondary hyperparathyroidism on hemodialysis
    Arenas, M. D.
    Muray, S.
    Arnoedo, M. L.
    Egea, J. J.
    Millan, J.
    Gil, M. I.
    NEFROLOGIA, 2006, 26 (02): : 226 - 233
  • [28] THE EFFECT OF LONG-TERM INTRAVENOUS CALCITRIOL ADMINISTRATION ON PARATHYROID FUNCTION IN HEMODIALYSIS-PATIENTS
    RODRIGUEZ, M
    FELSENFELD, AJ
    WILLIAMS, C
    PEDERSON, JA
    LLACH, F
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 1991, 2 (05): : 1014 - 1020
  • [29] Telomere shortening in patients on long-term hemodialysis
    Yucheng Wang
    Siyu Chen
    Shi Feng
    Cuili Wang
    Hong Jiang
    Song Rong
    Haller Hermann
    Jianghua Chen
    Ping Zhang
    慢性疾病与转化医学(英文), 2021, 07 (04) : 266 - 275
  • [30] Short- and long-term renal outcomes of immediate prophylactic hemodialysis after cardiovascular catheterizations in patients with severe renal insufficiency
    Hsieh, YC
    Ting, CT
    Liu, TJ
    Wang, CL
    Chen, YT
    Lee, WL
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2005, 101 (03) : 407 - 413